Organotin complexes with Schiff’s base ligands: insights into their cytotoxic effects on lung cancer cells

• Published in: Journal of Umm Al-Qura University for Applied Sciences
• Main Author: Ibadi F.; Yousif E.; Al-Ani A.; Al-Mashhadani M.; Al-Saffar A.Z.; Basem A.; Bufaroosha M.; Hashim H.; Husain A.; Jawad A.H.; Hairunisa N.
• Format: Article
• Language: English
• Published: Springer 2024
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85196742169&doi=10.1007%2fs43994-024-00170-w&partnerID=40&md5=5d0bd1ac68b2bf3f0b4fee2437eba1df

Organotin(IV) complexes can be used in chemotherapy due to its lipophilicity which can be affected by the availability of Sn coordination bond and bond stabilization between ligand and Sn(IV). In this study, three types of tri-organotin(IV) complexes which are, Ph3SnL, Me3SnL, and Bu3SnL derived from Schiff base ligand were synthesized by the reaction of methyl dopa with p-dimethyaminobenzaldehyde. All prepared complexes were charechterised using nuclear magnetic resonance (1H NMR, 13C NMR, and 119Sn NMR. The 1H NMR). The results confirm the coordination of the organotin(IV) moieties to the ligand. The cytotoxicity of tri-organotin(IV) complexes was evaluated against the A549 human lung cancer cell using MTT assay. Ph3SnL showed a high cytotoxic effect among othger complexes, Bu3SnL also showed a significant cytotoxic effect, while Me3SnL demonstrated a relatively lower effects. These findings highlight the potential of the tri-organotin(IV) complexes, particularly Ph3SnL and Bu3SnL, as promising candidates for further modification as anticancer agents. The results obtained from this study can be used to understand the structure–activity of organotin(IV) complexes and their applications as anti-cancer activity. © The Author(s) 2024.